Amarapurkar DN, Patel ND

Language: English
References: 11
Page: 56-59
PDF size: 40.18 Kb.

Text Extraction

Introduction: Treatment strategies for chronic hepatitis B (CHB) using either interferon or Lamivudine can achieve sustained response in 30-40 % in HBeAg positive CHB. Retreatment of treatment failure in CHB and treatment of HBeAg negative patients pose major therapeutic challenge. Because of success story of Peginterferon in hepatitis C and some preliminary data in CHB, we undertook this open-labeled prospective study to study the response of Peginterferon α-2b (PegIFN) and Lamivudine combination in patients of CHB. Materials and methods: Following 4 groups of patients of CHB with persistently elevated transaminases were treated with Lamivudine 100 mg PO daily and PegIFN 1.5 µg/kg SC once a week- 1) HBeAg negative treatment naïve patients- for 12 months 2) HBeAg negative patients who were nonresponsive to at least two treatment regimens- for 12 months, 3) HBeAg positive treatment naïve patients- for 6 months 4) HBeAg positive patients who were treatment failure at least with two regimens- for 6 months. Patients were tested for LFT, HBeAg, antiHBe, quantitative HBVDNA (only in HBeAg negative CHB) and liver biopsy when possible at inclusion. During treatment period, LFT was tested at monthly interval and HBeAg, antiHBe and HBVDNA (in HBeAg negative CHB) at 3 monthly intervals. End of treatment response (EOR) was assessed at end of treatment period and sustained response (SR) at 6 months post treatment. Treatment response was defined in HBeAg positive patients with normalization of enzymes and disappearances of HBeAg & in antiHBe positive patients with normalization of enzymes and loss of detectable HBVDNA. Results: Total 25 patients with CHB were included in this study with mean age of 37.9 ± 4.6 years (range 20-56) and male: female= 11.5:1. 1) In HBeAg negative treatment naïve patients, 4/6 patients achieved EOR (66.6%), whereas in 3/6 patients (50%) had SR. 2) In HBeAg negative treatment failure group, 4/5 patients had EOR (80%) and 3/5 patients achieved SR (60%), of which 1 patient lost HBsAg. 3) In HBeAg positive treatment naïve patients, 4/5 patients achieved EOR (80%) and 3/5 patients obtained SR (60%). One patient in this group lost HBsAg. 4) In HBeAg positive treatment failure group, 5/9 patients achieved EOR (55.5%), whereas 3/9 patients (33.3%) obtained SR. Conclusion: Overall, in difficult-to-treat patients (considering groups 1, 2 & 4- total 20 patients) with combination of PegIFN and Lamivudine, EOR was seen in 13 patients (65%), SR was obtained in 9 patients (45%) and loss of HBsAg was seen in 1 patient (5%).

REFERENCES

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.

2. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, ed. Viral hepatitis. New York: Marcel Dekker 1997: 315-330.

3. Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J viral hepatitis 2003; 10: 298-305.

4. Sung JJY, Chan HLY, Chan FKL, Chim AHL, Wong ML, Leung NWY. Combination of Pegylated interferon and Lamivudine is superior to Lamivudine monotherapy in the treatment of chronic hepatitis B- a randomized trial. J Hepatol 2003; 38 (suppl-2): 33.

5. Schalm SW. Combination therapy for chronic hepatitis B. J Hepatol 2003; 39: S146-S150.

6. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000- summary of a workshop. Gastroenterology 2001; 120: 1828-1853.

7. Lai CL, Chiewn RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of Lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.

8. Lok AS, McMahon BJ. Chronic hepatitis B- AASLD practice guidelines. Hepatology 2001; 34: 1225-1241.

9. Janssen HL, Schalm SW, Berk L, Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993; 17(suppl. 3): S47.

10. Schiff E, Karayalein S, Grimm I, Perrillo R, Dienstag J, Husa P, et al and the International Lamivudine Investigator Group. A placebo controlled study of Lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998; 28: 388A.

11. van Zonneveld M, van Nunen AB, Schalm SW, Janssen HLA. Chronic HBV treatment with one year of Pegylated- interferon alpha-2B (PEG-IFN) has a comparable safety profile to short-term conventional interferon alpha-2B. J Hepatol 2003; 38 (suppl-2): 179.